Study of chidamide, camrelizumab, and apatinib for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs for advanced esophageal squamous cell cancer that has been treated with 1 to 3 prior therapies. It aims to see if combining these drugs helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced esophageal squamous cell cancer that has spread or cannot be removed with surgery.
- You have had 1 to 3 previous treatments for advanced disease.
- If you had immunotherapy before, it must have worked for more than 6 months.
- You are between 18 and 75 years old.
- You are able to perform daily activities with minimal help (ECOG 0 or 1).
- You have good kidney, liver, heart, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This Phase 2 study tests whether combining camrelizumab (immunotherapy) and apatinib (a targeted drug) with short-course chemotherapy can control advanced esophageal squamous cell carcinoma. It may help by improving cancer response and slowing disease growth if you’re eligible and haven’t had prior whole-body (systemic) anti-cancer treatment.
This study tests a new combination of drugs (adebelimab, apatinib, and chemotherapy or chemoradiation) for people with esophageal cancer that has gotten worse after prior immunotherapy. It aims to see if this combination can help when standard first-line treatment stops working.
This trial tests a precision medicine approach for people with advanced esophageal cancer that has stopped responding to immunotherapy. The goal is to find better treatments based on each person's tumor biology.
This trial tests a combination of medicines to treat advanced esophageal squamous cell carcinoma (throat/esophagus cancer) that cannot be removed by surgery and has spread or come back. It is for people whose first treatment (chemotherapy or immunotherapy) did not work well or was not tolerated.
Hear when a new Advanced Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.